Mesenchymal stem cells as immunomodulator therapies for immune-mediated systemic dermatoses

Stem Cells and Development

Volumn 21, Issue 3, 2012, Pages 352-362

  Reddy, Bobby Y ^a   Xu, David S ^b   Hantash, Basil M ^c  

^a RUTGERS NEW JERSEY MEDICAL SCHOOL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c Elixir Institute of Regenerative Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; BETA1 INTEGRIN; CD146 ANTIGEN; CD20 ANTIBODY; CD44V ANTIGEN; CD63 ANTIGEN; CYCLOPHOSPHAMIDE; ENDOGLIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; INDOLEAMINE 2,3 DIOXYGENASE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MICROSOMAL AMINOPEPTIDASE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; PROSTAGLANDIN E2; THY 1 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BONE MARROW CELL; CD25+ T LYMPHOCYTE; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; GRAFT VERSUS HOST REACTION; HISTOCOMPATIBILITY COMPLEX; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; INNATE IMMUNITY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STEM CELL; MULTIPOTENT STEM CELL; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; T LYMPHOCYTE;

ADAPTIVE IMMUNITY; ANTIGEN-PRESENTING CELLS; BONE MARROW CELLS; CELL DIFFERENTIATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC FACTORS; IMMUNOMODULATION; LUPUS ERYTHEMATOSUS, SYSTEMIC; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; SKIN DISEASES;

EID: 84863417904     PISSN: 15473287     EISSN: 15578534     Source Type: Journal    
DOI: 10.1089/scd.2011.0404     Document Type: Review

References (81)

1. Friedenstein AJ, KV Petrakova, AI Kurolesova and GP Frolova. (1968). Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 6:230-247.
2. Haynesworth SE, J Goshima, VM Goldberg and AI Caplan. (1992). Characterization of cells with osteogenic potential from human marrow. Bone 13:81-88.
3. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, et al. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147. (Pubitemid 29282067)
4. Jiang Y, BN Jahagirdar, RL Reinhardt, RE Schwartz, CD Keene, XR Ortiz-Gonzalez, et al. (2002). Pluripotency of mesenchymal stem cells derived from adult marrow. Nature 418:41-49. (Pubitemid 34742565)
5. Campagnoli C, IAG Roberts, S Kumar, PR Bennett, I Bellantuono and NM Fisk. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98:2396-2402.
6. Erices A, P Conget and JJ Minguell. (2000). Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol 109:235-242. (Pubitemid 30340601)
7. Krampera M, S Glennie, J Dyson, D Scott, R Laylor, E Simpson, et al. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101:3722-3729. (Pubitemid 36857965)
8. Le Blanc K, L Tammik, B Sundberg, SE Haynesworth and O Ringden. (2003). Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 57:11-20. (Pubitemid 38019084)
9. Le Blanc K, C Tammik, K Rosendahl, E Zetterberg and O Ringden. (2003). HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol 31:890-896. (Pubitemid 37211373)
10. Friedenstein A and AI Kuralesova. (1971). Osteogenic precursor cells of bone marrow in radiation chimeras. Transplantation 12:99-108.
11. Prockop DJ. (1997). Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 276:71-74. (Pubitemid 27161245)
12. Bianco P and PG Robey. (2004). Skeletal stem cells. In: Handbook of Adult and Fetal Stem Cells Lanza RP, ed. Academic Press, San Diego, pp 415-424.
13. Muraglia A, R Cancedda and R Quarto. (2000). Clonal mesenchymal progenitors from human bone marrow differentiate in vitro according to a hierarchical model. J Cell Sci 113:1161-1166. (Pubitemid 30229533)
14. Conget PA and JJ Minguell. (1999). Phenotypical and functional properties of human bone marrow mesenchymal progenitor cells. J Cell Physiol 181:67-73. (Pubitemid 29400373)
15. Colter DC, R Class, CM DiGirolamo and DJ Prockop. (2000). Rapid expansion of recycling stem cells in cultures of plasticadherent cells from human bone marrow. Proc Natl Acad Sci U S A 97:3213-3218. (Pubitemid 30183281)
16. Minguell JJ, A Erices and P Conget. (2001). Mesenchymal stem cells. Exp Biol Med 226:507-520. (Pubitemid 32524497)
17. Jaiswal N, SE Haynesworth, AI Caplan and SP Bruder. (1997). Osteogenic differentiation of purified, cultureexpanded human mesenchymal stem cells in vitro. J Cell Biochem 64:295-312. (Pubitemid 27065443)
18. Bruder SP, N Jaiswal and SE Haynesworth. (1997). Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive sub-cultivation and following cryopreservation. J Cell Biochem 64:278-294. (Pubitemid 27065442)
19. Kadiyala S, RG Young, MA Thiede and SP Bruder. (1997). Culture expanded canine mesenchymal stem cells possess osteochondrogenic potential in vivo and in vitro. Cell Transplant 6:125-134. (Pubitemid 27188295)
20. Pereira RF, KW Halford, MD O'Hara, DB Leeper, BP Sokolov, MD Pollard, et al. (1995). Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci U S A 92:4857-4861.
21. Mackay AM, SC Beck, JM Murphy, FP Barry, CO Chichester and MF Pittenger. (1998). Chondrogenic differentiation of cultured human mesenchymal stem cells from marrow. Tissue Eng 4:415-428. (Pubitemid 28553528)
22. Jaiswal RK, N Jaiswal, SP Bruder, G Mbalaviele, DR Marshak and MF Pittenger. (2000). Adult human mesenchymal stem cell differentiation to the osteogenic or adipogenic lineage is regulated by mitogen-activated protein kinase. J Biol Chem 275:9645-9652. (Pubitemid 30185197)
23. Janderova L, M McNeil, AN Murrell, RL Mynatt and SR Smith. (2003). Human mesenchymal stem cells as an in vitro model for human adipogenesis. Obesity 11:65-74. (Pubitemid 41137540)
24. Liechty KW, TC MacKenzie, AF Shaaban, A Radu, AM Moseley, R Deans, et al. (2000). Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med 6:1282-1286.
25. Kopen GC, DJ Prockop and DG Phinney. (1999). Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A 96:10711-10716. (Pubitemid 29442209)
26. Mezey E, KJ Chandross, G Harta, RA Maki and SR McKercher. (2000). Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 290:1779-1782. (Pubitemid 32004811)
27. Trzaska KA, BY Reddy, JL Munoz, K-Y Li, J-H Ye and P Rameshwar. (2008). Loss of RE-1 silencing factor in mesenchymal stem cell-derived dopamine progenitors induces functional maturity. Mol Cell Neurosci 39:285-290.
28. Cho KJ, KA Trzaska, SJ Greco, J McArdle, FS Wang, JH Ye, et al. (2005). Neurons derived from human mesenchymal stem cells show synaptic transmission and can be induced to produce the neurotransmitter substance P by interleukin-1 alpha. Stem Cells 23:383-391. (Pubitemid 40404457)
29. Klyushnenkova E, JD Mosca, V Zernetkina, MK Majumdar, KJ Beggs, DW Simonetti, et al. (2005). T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J Biomed Sci 12:47-57. (Pubitemid 40576763)
30. Sotiropoulou PA, SA Perez, AD Gritzapis, CN Baxevanis and M Papamichail. (2006). Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 24:74-85.
31. Gokmen MR, G Lombardi and RI Lechler. (2008). The importance of the indirect pathway of allorecognition in clinical transplantation. Curr Opin Immunol 20:568-574.
32. Tse WT, JD Pendleton, WM Beyer, MC Egalka and EC Guinan. (2003). Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75:389-397. (Pubitemid 36222968)
33. Majumdar MK, M Keane-Moore, D Buyaner, WB Hardy, MA Moorman, KR McIntosh, et al. (2003). Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J Biomed Sci 10:228-241. (Pubitemid 36302404)
34. Potian JA, H Aviv, NM Ponzio, JS Harrison and P Rameshwar. (2003). Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J Immunol 171:3426-3434. (Pubitemid 37254543)
35. Spaggiari GM, A Capobianco, S Becchetti, MC Mingari and L Moretta. (2006). Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107:1484-1490. (Pubitemid 43242385)
36. Poggi A, C Prevosto, A-M Massaro, S Negrini, S Urbani, I Pierri, et al. (2005). Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J Immunol 175:6352-6360. (Pubitemid 41598875)
37. Reichert T, M DeBruyere, V Deneys, T Totterman, P Lydyard, F Yuksel, et al. (1991). Lymphocyte subset reference ranges in adult Caucasians. Clin Immunol Immunopathol 60:190-208.
38. Raffaghello L, G Bianchi, M Bertolotto, F Montecucco, A Busca, F Dallegri, et al. (2008). Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche. Stem Cells 26:151-162.
39. Beyth S, Z Borovsky, D Mevorach, M Liebergall, Z Gazit, H Aslan, et al. (2005). Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105:2214-2219. (Pubitemid 40731815)
40. Nauta AJ, AB Kruisselbrink, E Lurvink, R Willemze and WE Fibbe. (2006). Mesenchymal stem cells inhibit generation and function of both CD34 + -derived and monocyte-derived dendritic cells. J Immunol 177:2080-2087. (Pubitemid 44200965)
41. Aggarwal S and MF Pittenger. (2005). Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105:1815-1822. (Pubitemid 40223708)
42. Jiang X-X, Y Zhang, B Liu, S-X Zhang, Y Wu, X-D Yu, et al. (2005). Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105:4120-4126. (Pubitemid 40656164)
43. Maccario R, M Podesta, A Moretta, A Cometa, P Comoli, D Montagna, et al. (2005). Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90:516-525. (Pubitemid 40592895)
44. Rasmusson I, O Ringdén, B Sundberg and K Le Blanc. (2005). Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp Cell Res 305:33-41. (Pubitemid 40380651)
45. Najar M, R Rouas, G Raicevic, HI Boufker, P Lewalle, N Meuleman, et al. (2009). Mesenchymal stromal cells promote or suppress the proliferation of T lymphocytes from cord blood and peripheral blood: the importance of low cell ratio and role of interleukin-6. Cytotherapy 11:570-583.
46. Augello A, R Tasso, M Negrini Simone, A Amateis, F Indiveri, R Cancedda, et al. (2005). Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur J Immunol 35:1482-1490. (Pubitemid 40691430)
47. Corcione A, F Benvenuto, E Ferretti, D Giunti, V Cappiello, F Cazzanti, et al. (2006). Human mesenchymal stem cells modulate B-cell functions. Blood 107:367-372. (Pubitemid 43053565)
48. Ren G, L Zhang, X Zhao, G Xu, Y Zhang, AI Roberts, et al. (2008). Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide. Cell Stem Cell 2:141-150. (Pubitemid 351181031)
49. Selmani Z, A Naji, I Zidi, B Favier, E Gaiffe, L Obert, et al. (2008). Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4 + CD25highFOXP3 + regulatory T cells. Stem Cells 26:212-222.
50. Meisel R, A Zibert, M Laryea, U Gobel, W Daubener and D Dilloo. (2004). Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenasemediated tryptophan degradation. Blood 103:4619-4621. (Pubitemid 38745993)
51. Munn DH, M Zhou, JT Attwood, I Bondarev, SJ Conway, B Marshall, et al. (1998). Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281:1191-1193. (Pubitemid 28406294)
52. Sato K, K Ozaki, I Oh, A Meguro, K Hatanaka, T Nagai, et al. (2007). Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 109:228-234. (Pubitemid 46053063)
53. Di Nicola M, C Carlo-Stella, M Magni, M Milanesi, PD Longoni, P Matteucci, et al. (2002). Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99:3838-3843. (Pubitemid 34534559)
54. Liu J, XF Lu, L Wan, YP Li, SF Li, LY Zeng, et al. (2004). Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. Transplant Proc 36:3272-3275. (Pubitemid 41126790)
55. Maitra B, E Szekely, K Gjini, MJ Laughlin, J Dennis, SE Haynesworth, et al. (2004). Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant 33:597-604. (Pubitemid 38455921)
56. Chapel A, JM Bertho, M Bensidhoum, L Fouillard, RG Young, J Frick, et al. (2003). Mesenchymal stem cells home to injured tissues when co-infused with hematopoietic cells to treat a radiation-induced multi-organ failure syndrome. J Gene Med 5:1028-1038. (Pubitemid 40310427)
57. Pittenger MF and BJ Martin. (2004). Mesenchymal stem cells and their potential as cardiac therapeutics. Circ Res 95:9-20. (Pubitemid 38931831)
58. Glennie S, I Soeiro, PJ Dyson, EW Lam and F Dazzi. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105:2821-2827. (Pubitemid 40446275)
59. Champlin RE, N Schmitz, MM Horowitz, B Chapuis, R Chopra, JJ Cornelissen, et al. (2000). Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood 95:3702-3709.
60. Bensinger WI, PJ Martin, B Storer, R Clift, SJ Forman, R Negrin, et al. (2001). Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med 344:175-181. (Pubitemid 32064138)
61. Ferrara JLM, JE Levine, P Reddy and E Holler. (2009). Graftversus-host disease. Lancet 373:1550-1561.
62. Frassoni F, M Labopin, A Bacigalupo, E Gluckman, V Rocha, B Bruno, et al. (2005). Expanded mesenchymal stem cells (MSC), co-infused with HLA identical hemopoietic stem cell transplants, reduce acute and chronic graft versus host disease: a matched pair analysis. Bone Marrow Transplant [abstract] 29(Suppl 2):S2.
63. Ball LM, ME Bernardo, H Roelofs, A Lankester, A Cometa, RM Egeler, et al. (2007). Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 110:2764-2767. (Pubitemid 47523204)
64. Ning H, F Yang, M Jiang, L Hu, K Feng, J Zhang, et al. (2008). The correlation between cotransplantation of mesenchymal stem cells and higher recurrence rate in hematologic malignancy patients: outcome of a pilot clinical study. Leukemia 22:593-599. (Pubitemid 351386730)
65. Lazarus HM, ON Koc, SM Devine, P Curtin, RT Maziarz, HK Holland, et al. (2005). Cotransplantation of HLAidentical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 11:389-398. (Pubitemid 40542932)
66. Le Blanc K, I Rasmusson, B Sundberg, C Götherström, M Hassan, M Uzunel, et al. (2004). Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363:1439-1441. (Pubitemid 38586721)
67. Le Blanc K, F Frassoni, L Ball, F Locatelli, H Roelofs, I Lewis, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 371:1579-1586. (Pubitemid 351626841)
68. Gabrielli A, EV Avvedimento and T Krieg. (2009). Scleroderma. N Engl J Med 360:1989-2003.
69. Graham-Brown RAC and I Sarkany. (1983). Sclerodermalike changes due to chronic graft-versus-host disease. Clin Exp Dermatol 8:531-538. (Pubitemid 13051904)
70. Bos GM, GD Majoor, DW Slaaf, MJ van de Gaar, JS Weijmervan Velzen and PJ van Breda Vriesman. (1989). Similarity of scleroderma-like skin lesions in allogeneic and syngeneic bone marrow transplantation models. Transplant Proc 21:3262-3263. (Pubitemid 19119577)
71. Lawley TJ, GL Peck, HM Moutsopoulos, AA Gratwohl and AB Deisseroth. (1977). Scleroderma, Sjogren-like syndrome, and chronic graft-versus-host disease. Ann Intern Med 87:707-709. (Pubitemid 8262907)
72. Nelson JL, DE Furst, S Maloney, T Gooley, PC Evans, A Smith, et al. (1998). Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 351:559-562. (Pubitemid 28077562)
73. Artlett CM, JB Smith and SA Jimenez. (1998). Identification of fetal DNA and cells in skin lesions from women with systemic sclerosis. N Engl J Med 338:1186-1191. (Pubitemid 28180747)
74. Christopeit M, M Schendel, J Foll, LP Muller, G Keysser and G Behre. (2007). Marked improvement of severe progressive systemic sclerosis after transplantation of mesenchymal stem cells from an allogeneic haploidentical-related donor mediated by ligation of CD137L. Leukemia 22:1062-1064. (Pubitemid 351689891)
75. Pistiner M, DJ Wallace, S Nessim, AL Metzger and JR Klinenberg. (1991). Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 21:55-64.
76. Cohen PL and RA Eisenberg. (1991). Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9:243-269.
77. Sun L, K Akiyama, H Zhang, T Yamaza, Y Hou, S Zhao, et al. (2009). Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 27:1421-1432.
78. Bombardier C DD Gladman, MB Urowitz, et al. (1992). Derivation of the SLEDAI: A Disease Activity Index for Lupus Patients Wiley, Hoboken, NJ, ETATS-UNIS.
79. Carrion F, EL Nova, CS Ruiz, FO Diaz, CS Inostroza, DM Rojo, et al. (2010). Autologous mesenchymal stem cell treatment increased T regulatory cells with no effect on disease activity in two systemic lupus erythematosus patients. Lupus 19:317-322.
80. Sun LY, HY Zhang, XB Feng, YY Hou, LW Lu and LM Fan. (2007). Abnormality of bone marrow-derived mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 16:121-128. (Pubitemid 46347934)
81. Nie Y, CS Lau, AKW Lie, GCF Chan and MY Mok. (2010). Defective phenotype of mesenchymal stem cells in patients with systemic lupus erythematosus. Lupus 19:850-859.